Protein-losing Enteropathy

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Protein-losing enteropathy (PLE) occurs in a number of gastrointestinal (GI) conditions that cause excessive loss of serum proteins into the GI tract.[1] Three main mechanisms are involved:

Mucosal disease with ulceration with protein loss across disrupted mucosal surface

NEW - log your activity

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »

Lymphatic obstruction causing loss of protein-rich chyle

Idiopathic alterations in mucous capillary permeability

Because the condition is so multifactorial, the prevalence rate is not known.

Consider protein-losing enteropathy (PLE) in any patient presenting with oedema, especially if this is against a background of GI disease.

History

  • A dietary history should be taken to exclude malnutrition as a cause of reduced albumin synthesis.
  • Check the patient's medical history for information about renal disease (increased protein loss) or hepatic disease (reduced albumin synthesis).
  • Ask about GI symptoms, in particular any symptoms suggestive of enteritis (eg diarrhoea, abdominal pain).
  • Ask about alcohol intake.
  • Check for a history of congenital heart disease, episodes of pericarditis, serious streptococcal infection, or prior heart surgery (increased interstitial pressure can be a cause).

Examination

  • Check the general nutritional status of the patient - eg height, weight, head circumference in children.
  • Look for signs of acute liver disease (eg enlarged liver, tenderness in the right upper quadrant).
  • Look for signs of chronic liver disease (eg jaundice, splenomegaly, prominent veins on the abdomen).
  • Check for signs of right heart failure - eg ascites and jugular vein distension.
  • The finding of high blood pressure may suggest renal or cardiac disease.
  • Look for signs of GI pathology - eg abdominal tenderness, macroscopic or microscopic blood and mucus in the stool.
  • Collagenous and lymphocytic colitis
  • Hypoalbuminaemia
  • Hypogammaglobulinaemia
  • Inflammatory bowel disease
  • Malabsorption
  • Mycoplasma infections
  • Pericarditis
  • Restrictive cardiomyopathy
  • Salmonellosis
  • Yersinia enterocolitica
  • Serum proteins - by definition hypoalbuminaemia will be present.
  • Liver and renal disease should be excluded by the appropriate function tests.
  • Evidence of protein loss via the GI tract should be investigated in patients with oedema, hypoalbuminaemia and normal renal and liver function tests.
  • Raised alpha-1-antitrypsin levels in stools is a marker for protein loss but is not very specific as this is also seen in liver disease.
  • Viral serologies may be useful.[3]
  • Scintigraphy is a more accurate test. It involves the use of radio-labelled substances which are administered intravenously and then detected by the use of serial abdominal X-rays. The two common agents used are technetium-labelled (Tc-99m) dextran[4] or human serum albumin. These substances have been chosen because they are readily available (and therefore cheap), easy to administer and inert.
  • Upper and/or lower endoscopy and mucosal biopsies may be needed to elucidate underlying causes.

Nondrug

In lymphatic obstruction patients should in theory be helped by a low-fat diet with medium-chain triglyceride supplement.[5] However, in practice this results in increased blood flow with no reduction in faecal protein loss.

Drugs

  • The importance of treating the underlying cause cannot be overestimated. One study reported the resolution of protein-losing enteropathy (PLE) by the simple measure of treating the patient's chronic diarrhoea with loperamide.The use of diuretics for congestive heart failure is another example.[6]
  • Octreotide has been shown to be useful in some patients.[7] It is a potent inhibitor of many hormones affecting the gut and has a marked effect on reducing blood flow to the intestines.
  • Supplementation with fat-soluble vitamins may be helpful.
  • PLE is a common complication of Fontan's operation. This is a procedure carried out in children with severe congenital heart disease in which venous blood is diverted from the right atrium to the pulmonary arteries without passing through the right ventricle. Heparin produces benefits independent of its anticoagulant effect.[8] Steroids can be an effective therapy but must be continued long-term at a low dose.[9]

Surgery

  • In patients who have undergone Fontan's procedure, making a window in the baffle that separates the systemic venous pathway from the pulmonary venous atrium has helped to resolve PLE, presumably due to a reduction in systemic venous pressure.
  • In patients whose PLE is secondary to a cardiac cause (eg restrictive cardiomyopathy, constrictive pericarditis, tricuspid valvar stenosis and insufficiency), restoration of the unobstructed flow of blood in the superior or inferior caval vein may be curative. Post-Fontan patients may benefit but are unlikely to be cured.[10]
  • Cardiac transplant is occasionally used to treat intractable PLE in patients who have had previous heart surgery.
  • PLE after Fontan's operation associated with lymphangiectasia (blockage of the intestinal lymphatics) has been successfully treated by resection of the affected area of bowel.[11]

This depends on the underlying disease but improved management techniques are reducing mortality and morbidity of many causes. More than half the patients presenting with protein-losing enteropathy (PLE) now reach partial or complete remission but require regular monitoring of their nutritional status.[12]

Further reading & references

  1. Aslam N et al, Protein-Losing Enteropathy, Medscape, Jul 2008
  2. Meadows J, Gauvreau K, Jenkins K; Lymphatic obstruction and protein-losing enteropathy in patients with congenital heart disease. Congenit Heart Dis. 2008 Jul;3(4):269-76.
  3. Rabinowitz S, Protein-Losing Enteropathy, Medscape, Aug 2009
  4. Kapoor S, Ratan SK, Kashyap R, et al; Detecting protein losing enteropathy by Tc-99m dextran scintigraphy: a novel experience. Indian J Pediatr. 2002 Sep;69(9):761-4.
  5. Vignes S, Bellanger J; Primary intestinal lymphangiectasia (Waldmann's disease). Orphanet J Rare Dis. 2008 Feb 22;3:5.
  6. Windram JD, Clift PF, Speakman J, et al; An Unusual Treatment for Protein Losing Enteropathy. Congenit Heart Dis. 2011 Mar 21. doi: 10.1111/j.1747-0803.2011.00484.x.
  7. Kuroiwa G, Takayama T, Sato Y, et al; Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol. 2001 Feb;36(2):129-32.
  8. Ryerson L, Goldberg C, Rosenthal A, et al; Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation. Am J Cardiol. 2008 Jan 15;101(2):248-51.
  9. Thacker D, Patel A, Dodds K, et al; Use of oral budesonide in the management of protein-losing enteropathy after the Ann Thorac Surg. 2010 Mar;89(3):837-42.
  10. Menon S, Hagler D, Cetta F, et al; Role of caval venous manipulation in treatment of protein-losing enteropathy. Cardiol Young. 2008 Jun;18(3):275-81. Epub 2008 Mar 7.
  11. Connor FL, Angelides S, Gibson M, et al; Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium-dextran scintigraphy. Pediatrics. 2003 Sep;112(3 Pt 1):e242-7.
  12. Madison Foundation; Protein-Losing Enteropathy

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Laurence Knott
Current Version:
Last Checked:
23/05/2011
Document ID:
1730 (v23)
© EMIS